OTCPK:SHPHF (China)
Â
$
0.07
+0.0075 (+13.04%)
10:08 PM EST
Business Description
Sihuan Pharmaceutical Holdings Group Ltd
NAICS : 325414
ISIN : BMG8162K1137
Compare
Compare
Traded in other countries / regions
00460.Hong KongTEL1.GermanySHPHF.USA IPO Date
2011-11-14Description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segments; and the generic medicine segment which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.57 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 5.64 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.96 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10.8 | |||||
| 3-Year EBITDA Growth Rate | -33.4 | |||||
| 3-Year FCF Growth Rate | 37 | |||||
| 3-Year Book Growth Rate | -23.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 99.49 | |||||
| 14-Day RSI | 94.94 | |||||
| 6-1 Month Momentum % | 44.44 | |||||
| 12-1 Month Momentum % | -18.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.51 | |||||
| Quick Ratio | 1.37 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 367.84 | |||||
| Days Sales Outstanding | 85.38 | |||||
| Days Payable | 124.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 32.2 | |||||
| 3-Year Average Share Buyback Ratio | 0.5 | |||||
| Shareholder Yield % | 0.62 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 65.93 | |||||
| Operating Margin % | -15.2 | |||||
| Net Margin % | -2.14 | |||||
| FCF Margin % | -5.49 | |||||
| ROE % | -0.82 | |||||
| ROA % | -0.31 | |||||
| ROIC % | -5.28 | |||||
| 3-Year ROIIC % | 81.51 | |||||
| ROC (Joel Greenblatt) % | 4.05 | |||||
| ROCE % | 1.33 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 8.19 | |||||
| PS Ratio | 2.68 | |||||
| PB Ratio | 1.06 | |||||
| Price-to-Tangible-Book | 1.3 | |||||
| Price-to-Operating-Cash-Flow | 23.91 | |||||
| EV-to-EBIT | 12.23 | |||||
| EV-to-EBITDA | 6.53 | |||||
| EV-to-Revenue | 0.84 | |||||
| EV-to-FCF | -15.18 | |||||
| Price-to-Projected-FCF | 0.65 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Earnings Yield (Greenblatt) % | 8.18 | |||||
| FCF Yield % | -2.05 | |||||
| Forward Rate of Return (Yacktman) % | 26.31 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers